The ShcA adapter protein transmits activating signals downstream of receptor and cytoplasmic tyrosine kinases through the establishment of phosphotyrosine-dependent complexes. In this regard, ShcA ...
Prof. You-Me Kim and her student Dajung Jung at Pohang University of Science and Technology (POSTECH), in collaboration with Prof. Wonhwa Cho's group at the University of Illinois at Chicago, have ...
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced data will be presented at the ...
Recludix Pharma has launched with $60 million in series A funding to use DNA-encoded libraries to discover small-molecule drugs. The start-up’s focus is on inhibiting SH2 domains, protein structures ...
The adaptor molecule, Cbl, is involved as a negative regulator in a number of cell signaling pathways. Among its targets are cell surface receptors such as that for epidermal growth factor, and the ...
The MarketWatch News Department was not involved in the creation of this content. -- Financing led by institutional investors, with participation from new investor Eli Lilly and Company -- Inclusive ...
Majority of human Src homology 2 (SH2) domains not only bind to proteins, but also interact with membrane lipids with high affinity and specificity. The SH2 domain-containing proteins play important ...
-- Bruton's tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) --BTK inhibition through the SH2 domain results in ...
Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results